w66国际·利来(中国)最给力的老牌

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF BENMELSTOBART INJECTION IN COMBINATION WITH ANLOTINIB HYDROCHLORIDE CAPSULE FOR THE INDICATION OF TREATMENT FOR ENDOMETRIAL CANCER

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF ANLOTINIB HYDROCHLORIDE CAPSULE IN COMBINATION WITH PENPULIMAB INJECTION FOR FIRST-LINE TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA

VOLUNTARY ANNOUNCEMENT - SIGNING EQUITY INVESTMENT AND STRATEGIC COOPERATION AGREEMENT WITH LANOVA MEDICINES

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY

VOLUNTARY ANNOUNCEMENT - APPROVAL GRANTED FOR CLINICAL TRIALS OF THE FOURTH-GENERATION EGFR INHIBITOR "TQB3002" IN THE UNITED STATES

VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF KRAS G12C INHIBITOR “GARSORASIB” TABLET

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2024

CONNECTED TRANSACTION IN RELATION TO (1) ACQUISITION OF 29.99% EQUITY INTEREST IN THE TARGET COMPANY; AND (2) POSSIBLE VOLUNTARY PARTIAL OFFER TO ACQUIRE A MAXIMUM OF 25.01% EQUITY INTEREST IN THE TARGET COMPANY